Factory 99% Abemaciclib Powder CAS 1231929-97-7 Chemical Intermediate Abemaciclib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A891
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Abemaciclib
• CAS: 1231929-97-7
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Abemaciclib
Appearance	White Powder
CAS NO.	1231929-97-7
Storage	Keep in a cool, dry, dark location

 

Abemaciclib is a potent oral inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6), developed by Eli Lilly and Company. It is a key therapeutic agent in the treatment of specific types of breast cancer.

 

1. Breast Cancer Treatment: Abemaciclib is approved for the treatment of hormone receptor-positive (HR+), human epidermal receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is indicated for use in both pre-menopausal and post-menopausal women.

2. Combination Therapy: The drug is often used in combination with other therapies, such as postmenopausal women for women who have progressed on endocrine therapy. This combination approach aims to enhance the therapeutic response and delay disease progression.

3. Monotherapy: In certain cases, Abemaciclib may be prescribed as a monotherapy for patients with HR+, HER2- advanced or metastatic breast cancer who have progressed on prior endocrine therapy and chemotherapy.

1. CDK4/6 Inhibition: The primary function of Abemaciclib is to inhibit the activity of CDK4 and CDK6, which are key regulators of the cell cycle. By blocking these enzymes, Abemaciclib prevents cancer cells from progressing through the cell cycle, leading to cell cycle arrest and ultimately, cell death.

2. Antiproliferative Effects: By inhibiting CDK4/6, Abemaciclib suppresses the proliferation of cancer cells, particularly in HR+ breast cancer, where CDK4/6 signaling is frequently dysregulated. This antiproliferative effect contributes to tumor regression and disease stabilization.

3. Enhanced Therapeutic Response: When used in combination with other therapies, such as endocrine therapy, Abemaciclib has been shown to enhance the therapeutic response and prolong progression-free survival in patients with HR+, HER2- advanced or metastatic breast cancer. This synergistic effect underscores the importance of Abemaciclib in the management of this disease.